Abstract:Abstract Nutrients in the tumor microenvironment play an essential role in tumor development and proudly impact cancer metabolism. The xCT antiporter, which mediates cellular uptake of L-cystine coupled with glutamate export, has been considered as a promising therapeutic target due in part to its high expression in cancer cells to promote L-cystine uptake as a precursor for glutathione (GSH) synthesis to maintain redox homeostasis. Although inhibition of xCT has been shown to have anticancer effect in multiple models, emerging evidence also reveals that blocking xCT function could confer survival advantages to cancer cells. These opposite observations suggest that xCT inhibition could be a double-edged sword, and its impact on the overall outcome (cancer-inhibitory or tumor-promoting) is likely context-dependent via yet unknown mechanisms. Here, we show that the expression of glutathione peroxidase 4 (GPX4) is a key molecular determinant that decides the cell fate when xCT is suppressed. In cells with low or no expression of GPX4, inhibition of xCT causes severe ROS stress leading to massive cell death via ferroptosis. In contrast, high expression of GPX4 confers cancer cells the ability to escape ROS-induced ferroptosis. Mechanistic study suggests that the intracellular L-cysteine plays a major role in regulating GPX4 protein level, likely via direct binding to GPX4 and stabilize the protein. Pharmacological and genetic disruption of xCT in cancer cells induces dramatic ferroptosis in culture conditions lacking L-cysteine, whereas the presence of L-cysteine in culture or in vivo renders cancer cells resistance to xCT abrogation. Importantly, genetic knockout of xCT by CRISPR/cas9 reduces cancer cell proliferation in culture but promotes tumor growth in vivo, suggesting that the metabolic changes induced by xCT disruption favor cell growth in vivo. Biochemical and molecular analyses show that the in vivo microenvironment containing L-cysteine enables the xCT-disrupted cells to maintain a high GPX4 level, and thus prevents ferroptosis. Furthermore, metabolic flux using U-13C5 glutamine reveals that xCT abrogation leads to intracellular accumulation of more glutamate, which promotes cancer cell survival and proliferation in the low glucose tissue microenvironment in vivo. Our study has identified GPX4 as a key molecule that determines cell fate under metabolic stress induced by xCT suppression, and suggests that modulation of L-cystine/cysteine metabolism might be an effective strategy to overcome ferroptosis-resistant cancer cells. Citation Format: Yanyu Zhang, Peng Huang. Ferroptosis induced by xCT abrogation is dependent on GPX4 protein expression regulated by L-cystine/cysteine metabolism [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3568.

Mo1040 THE ROLE OF MKP-5-P38/MAPK PATHWAY IN CLOPIDOGREL-INDUCED GASTRIC MUCOSAL EPITHELIAL CELLS APOPTOSIS AND TJ INTEGRITY DYSFUNCTION

ACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis

CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.

Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer

Role of MKP-5-p38/MAPK Pathway in Clopidogrel-induced Gastric Mucosal Epithelial Cells Apoptosis and Tight Junction Dysfunction.

MGST1 Expression Is Associated with Poor Prognosis, Enhancing the Wnt/β-Catenin Pathway via Regulating AKT and Inhibiting Ferroptosis in Gastric Cancer

AOC1 Contributes to Tumor Progression by Promoting the AKT and EMT Pathways in Gastric Cancer.

CircRHOT1 restricts gastric cancer cell ferroptosis by epigenetically regulating GPX4

N 6 -methyladenosine (m 6 A) writer METTL5 represses the ferroptosis and antitumor immunity of gastric cancer

CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer

KLK6 mediates stemness and metabolism of gastric carcinoma cells via the PI3K/AKT/mTOR signaling pathway

CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1

Abstract 1696: ACTL6A deficiency drives cell death through KLF4-involved chromatin accessibility changes in colorectal cancer

Abstract 3568: Ferroptosis Induced by Xct Abrogation is Dependent on GPX4 Protein Expression Regulated by L-cystine/cysteine Metabolism

HCP5 Derived Novel Microprotein Triggers Progression of Gastric Cancer through Regulating Ferroptosis

ARHGAP6 Suppresses Breast Cancer Tumor Growth by Promoting Ferroptosis via RhoA-ROCK1-p38 MAPK Signaling

Downregulation of Mir-221-3p Promotes the Ferroptosis in Gastric Cancer Cells Via Upregulation of ATF3 to Mediate the Transcription Inhibition of GPX4 and HRD1.

PRMT6 Promotes the Immune Evasion of Gastric Cancer by Upregulating ANXA1

Long non-coding RNA GATA6-AS1 is mediated by N6-methyladenosine methylation and inhibits the proliferation and metastasis of gastric cancer

Role of ATP citrate lyase and its complementary partner on fatty acid synthesis in gastric cancer

High expression of AlkB homolog 5 suppresses the progression of non‐small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11